• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Brian Buntz

BREAKING: FDA authorizes Pfizer’s COVID-19 vaccine

December 11, 2020 By Brian Buntz

The U.S. FDA tonight authorized the COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX), providing a much-hoped-for tool to roll back the deadly coronavirus pandemic. The FDA authorization came a day after an advisory commission for the agency provided an upbeat assessment of the two companies’ vaccine. The agency is also coordinating with the CDC and the […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance Tagged With: BioNTech, coronavirus, COVID-19, COVID-19 vaccine, FDA, Pfizer

While FDA advisory panel backs Pfizer’s COVID-19 vaccine, patient advocates urge caution

December 10, 2020 By Brian Buntz

Today, an FDA advisory panel recommended that the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) be granted emergency use authorization (EUA). A total of 77% of the 22 panelists voted “yes” to issue an EUA for the vaccine. In the past week, three countries — UK, Canada and Bahrain — granted emergency use […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance, Research & Development Tagged With: BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Pfizer

Canada signs off on Pfizer-BioNTech COVID-19 vaccine

December 9, 2020 By Brian Buntz

Canada’s health regulator has authorized the COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX).  Pfizer submitted documentation related to the BNT162b2 vaccine to Canadian regulators on Oct. 9, 2020.   “Canadians can feel confident that the review process was rigorous and that we have strong monitoring systems in place,” Health Canada explained in a statement. The agency also stressed […]

Filed Under: Business/Financial News, Featured, Regulatory/Compliance Tagged With: BioNTech, coronavirus, COVID-19, Health Canada, Pfizer, vaccines

7 takeaways about the COVID-19 vaccine from infectious disease expert Paul Offit 

December 3, 2020 By Brian Buntz

Dr. Paul Offit is one of the most notable vaccine experts in the U.S. A member of the FDA’s Vaccines and Related Biological Products Advisory Committee for COVID-19 vaccines, Offit is the co-inventor of a rotavirus vaccine. In a conversation with JAMA editor-in-chief Dr. Howard Bauchner, Offit shared his opinion on a range of subjects […]

Filed Under: Clinical Trials, Research & Development

Regeneron antibody cocktail wins emergency use authorization

November 24, 2020 By Brian Buntz

Regeneron Pharmaceuticals (NSDQ:REGN) has announced that the FDA has granted emergency use authorization (EUA) for the combination of casirivimab and imdevimab to treat COVID-19. The monoclonal antibody cocktail is reportedly the first treatment to show “statistically significant anti-viral activity” against COVID-19, according to its developer. In a trial, the combination of drugs cut hospitalization or emergency […]

Filed Under: Biotech, Featured, Hospital Care, Pharmaceutical Tagged With: Clinical Trials, coronavirus, COVID-19, Regeneron

5 takeaways from the latest White House Coronavirus Task Force meeting

November 20, 2020 By Brian Buntz

The White House Coronavirus Task Force promised a swift rollout of COVID-19 vaccines — but one of a number of takeaways from its first briefing since July. The briefing yesterday gave the task force a chance to once again urge Americans to heed COVID-19 guidance while also providing an update on vaccines and therapeutics. The […]

Filed Under: Biotech, Clinical Trials Tagged With: coronavirus, COVID-19, Moderna, Pfizer

Why the COVID-19 vaccine market won’t be ‘winner take all’

November 17, 2020 By Brian Buntz

There are a dozen Phase 3 COVID-19 vaccine candidates with more than 50 in either Phase 1 or Phase 2 trials. But the fact that Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have vaccine candidates with efficacy greater than 90% could ultimately narrow the playing field. “Efficacy matters, but I don’t think [Pfizer’s and Moderna’s efficacy rate of] greater […]

Filed Under: Biotech, Clinical Trials, Featured, Research & Development Tagged With: Clinical Trials, coronavirus, COVID-19, Moderna, Pfizer

Moderna and Pfizer COVID-19 vaccines set a high bar for competitors

November 16, 2020 By Brian Buntz

Moderna (NSDQ:MRNA) is now the second company to release positive preliminary results from a Phase 3 trial of a COVID-19 vaccine candidate — and it appears to be more good news. Last week, Pfizer (NYSE:PFE) announced that early data suggested its BNT162 mRNA-based vaccine was more than 90% effective at reducing symptomatic COVID-19 infections. Today, […]

Filed Under: Biotech, Clinical Trials, Pharmaceutical Tagged With: Clinical Trials, coronavirus, COVID-19, Moderna, Pfizer

What a Biden administration could mean for the pharma industry

November 13, 2020 By Brian Buntz

While President Trump continues to refuse to concede the election, a growing number of business associations and politicians have acknowledged Biden as the president-elect. What a Biden presidency would mean for the pharmaceutical industry continues to be an open question as the Senate outcome remains undecided, but two broadly similar outcomes are likely. Get the […]

Filed Under: Featured, Pharmaceutical, Regulatory/Compliance Tagged With: coronavirus, COVID-19, Joe Biden, pharmaceutical industry

Qiagen readies portable digital COVID-19 antigen test

November 12, 2020 By Brian Buntz

Qiagen (NYSE: QGEN) and its partner Ellume are gearing up for the launch of the QIAreach SARS-CoV-2 antigen test, which can reportedly process samples in 2–15 minutes. Qiagen notes that the test can process up to 30 swab samples per hour while supporting parallel processing of antibody tests. The companies have submitted the test for […]

Filed Under: Business/Financial News, Diagnostics Tagged With: Abbott, antigen test, coronavirus, COVID-19, Qiagen N.V., Roche

How AI could reassure you that COVID-19 vaccines are safe

November 12, 2020 By Brian Buntz

As governments and health authorities worldwide gear up to deliver potentially billions of COVID-19 vaccine doses, artificial intelligence and data automation techniques could be a powerful tool combating one of the top hindrances to mass vaccination: vaccine hesitancy. In particular, natural language processing (NLP) could help health authorities transform adverse event reports from COVID-19 vaccines […]

Filed Under: Big Data, Electronic Medical Records (EMR), Health Technology, Software / IT Tagged With: adverse events, coronavirus, COVID-19, IQVIA, natural language processing, NLP

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS